doi: 10.3389/fendo.2025.1568059 Received 28 January 2025 Accepted 10 April 2025 Published 30 April 2025 Volume 16 - 2025 Edited by Joao Dts Anselmo, Hospital do Divino Esprito Santo, Portugal Reviewed by Lucile Butruille, Musum National dHistoire Naturelle, France Updates Copyright 2025 Khudair, Khudair, Niinuma, Habib and Butler
The expanded 5-part metabolic protocol: a GLP receptor agonist, 5-Amino-1MQ, injectable SLU-PP-332, MOTS-c and Glutathione
The vial is reconstituted with bacteriostatic water before the first injection, kept refrigerated, and used within a defined window
Non-alcoholic fatty liver disease (NAFLD) can progress to NASH, a major risk factor for liver cancer [95]
But the medications were not designed to leave the picture quietly
This study assesses the role of L-carnitine and acetyl L-carnitine supplements in managing elongated morphology